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Background: Inducing donor-specific tolerance in renal transplant patients could potentially prevent allograft
rejection and calcineurin inhibitor nephrotoxicity. Combined kidney and hematopoietic stem cell transplant from
an HLA-matched donor is an exploratory and promising therapy to induce immune tolerance. Investigtion of
molecular mechanisms involved in the disease is needed to understand the potential process of cell therapy and
develop strategies to prevent this immunologic rejection.
Methods: We enrolled nine patients in a clinical study in which cryopreserved donor hematopoietic stem cells
were infused on days 2, 4, and 6 after kidney transplantation. One month post-transplant, 4 plasma samples were
collected from combined transplants (C + Tx), and 8 plasma samples from patients with kidney transplantation
alone (Tx). High abundance proteins in plasma were depleted and the two-dimensional liquid
chromatography-tandem mass spectrometry coupled with iTRAQ labeling was utilized to identify the protein
profiling between the two groups. Clusters of up- and down-regulated protein profiles were submitted to
MetaCore for the construction of transcriptional factors and regulation networks.
Results and Discussion: Among the 179 identified proteins, 65 proteins were found in C+ Tx with at least a 2-fold
change as compared with Tx. A subset of proteins related to the complement and coagulation cascade, including
complement C3a,complement C5a, precrusors to fibrinogen alpha and beta chains,was significantly downregulated
in C + Tx. Meanwhile, Apolipoprotein-A1(ApoA1), ApoC1, ApoA2, ApoE, and ApoB were significantly lower in Tx
compared to C+ Tx. Gene ontology analysis showed that the dominant processes of differentially expressed
proteins were associated with the inflammatory response and positive regulation of plasma lipoprotein particle
remodeling.
Conclusions: Thus, our study provides new insight into the molecular events in the hematopoietic stem
cell-induced immunologic tolerance.
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Although renal transplantation is an effective therapy of
end-stage renal failure, a significant proportion of organs
are lost every year due to chronic allograft rejection and
immunosuppressive drugs toxicity. The induction of im-
mune tolerance has the potential to prevent this chronic
rejection and drug toxicity. Immune tolerance of organ
transplants has been induced in laboratory animals by
infusing organ recipients with hematopoietic stem cells
(HSC) from the organ donor before or after transplant-
ation [1,2]. The continued presence of the organ donor’s
immune cells in the recipient’s thymus and peripheral
lymphoid tissue eliminates T-cell clones that could react
to alloantigens of the graft, thereby promoting and main-
taining immune tolerance [3,4].
At present, few clinical centers have addressed this issue.
Thus, the molecular mechanisms of stem cell-induced im-
munologic tolerance in human remains unknown. A more
thorough understanding of HSC transplantation-induced
immune tolerance would lead to a more successful treat-
ment of renal transplant patients. Our clinical study
showed that the recipients of combined kidney and HSC
transplants maintained stable kidney function with a
decreased dose of immunosuppressive agents during the
up to 29 months follow up. The present study uses
iTRAQ labeling and quantitative proteomics technology
to explore the potential mechanism involved in this cell
therapy. We hypothesized that these new insights into
the molecular basis of HSC-induced immunologic toler-
ance could be used to identify novel targets for the pre-
vention of immunologic rejection.
Materials and Methods
Transplanted patients
The study had been registered in Chinese Clinical Trial
Registry (http://www.chictr.org/, ChiCTR-TNC-09000399)
and had obtained consents from patients of combined
HSC and kidney transplantation. Potassium-EDTA plasma
samples were collected by venipuncture from the 12
patients undergoing renal transplant. These patients
included 8 kidney transplantation recipients with only
organ transplantation (Tx) and 4 patients with combined
HSC and kidney transplantation (C +Tx) at Zhongshan
Hospital (Shanghai, China). Plasma samples were col-
lected from each patient before surgery (Pre-Tx) and one
month after surgery. The collected plasma was aliquoted
and stored frozen at −80°C. All patient samples were
obtained with informed consent and ethical approval by
the Ethics Board of ZhongShan Hospital.
Hematopoietic Cell Transplantation
Before collecting hematopoietic cells, the donor received
a 5-day course of subcutaneous injections of granulocyte
colony-stimulating factor (G-CSF) at a dose of 7.5 mgper kilogram per day. G-CSF mobilized donor mono-
nuclear cells into the peripheral blood, and these cells
were harvested by the com.tec blood cell separator (Fre-
senius AG, Germany). CD34+ and CD3+ cells were
assessed by flow-cytometric analysis. One day before the
transplantation, donor HSC were harvested and stored
on −70°C. Total lymphoid irradiation was performed on
day −3,-2 and −1. We used SIEMENS Linac (ONCOR),
6MV photon beam with multileaf collimator (MLC), a
pattern of 480~510 cGy/3Fx/3D, 160~170 cGy/1Fx per
single fraction. Patients received irradiation to all major
lymphatic regions using anterior-posterior-posterior-
anterior (AP/PA) fields. The supradiaphragmatic or
“mantle” field encompassed the low cervical, supraclavi-
cular, infraclavicular, axillary, mediastinal, and pulmonary
hilar nodes, as well as the thymus [5,6]. During the oper-
ation, patients received 50 mg of rabbit antithymocyte
globulin [7].
On post-operative day 2, 4, and 6, patients received an
intravenous infusion of cryopreserved donor cells, which
included CD34+ cells (0.20-3.0 × 106 per kilogram).
Patients were treated with a classic triple immunosup-
pressive regimen of tacrolimus/prednisone/mycophenolate
mofetil or ciclosporin A/prednisone/mycophenolate mofe-
til. Microchimerism was determined by means of DNA
genotyping of simple sequence-length polymorphic mar-
kers that encode short tandem repeats (AmpFl STR Iden-
tifiler PCR Amplification Kit, Applied Biosystems).
Immunodepletion of high-abundance proteins
High abundance proteins in plasma were depleted using
Agilent Multiple Affinity Removal Column - Human 14
(MARS) kit (Agilent Technologies) as described in our
previous report [8].
Protein digestion and labeling with iTRAQ reagents
The proteins of each sample were denatured, alkylated,
and digested with sequencing-grade modified trypsin
with a protein-to enzyme ratio of 20:1 at 37°C overnight
and then labeled with the iTRAQ tags (Applied Biosys-
tems, Warrington, UK) as follows: pre-transplantation
patients −113 tag; C +Tx −115 tag; Tx −119 tag. The
labeled digests were then mixed and dried. The iTRAQ
technique allows the differential labeling of peptides
from distinct proteomes [9,10].
Off-line 2D LC-MS/MS
The combined peptide mixture was fractionated by
strong cation exchange (SCX) chromatography on a
20 AD high-performance liquid chromatography (HPLC)
system (Shimadzu, Kyoto, Japan). The concentrated
iTRAQ labelled sample was added to loading buffer
(10 mM KH2PO4 in 25% acetonitrile, pH 2.6) and loaded
onto the column. Buffer A was identical in composition
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fer A with 350 mM KCl. Separation was performed using
a linear binary gradient of 0–80% buffer B in buffer A at
a flow rate of 200 ml/min for 60 min. The absorbance at
214 nm and 280 nm was monitored and a total of 32
SCX fractions was collected along the gradient. These
fractions were dried down by the rotary vacuum concen-
trator, dissolved in buffer C (5% acetonitrile, 0.1% FA)
and analyzed on a QSTAR XL system (Applied Bio-
systems) interfaced with a 20 AD HPLC system
(Shimadzu). Peptides were separated on a Zorbax
300SB-C18 column (Agilent Technologies). The HPLC
gradient was 5–35% buffer B (95% acetonitrile, 0.1% FA)
in buffer A (5%ACN, 0.1% FA) at a flow rate of 0.3 ml/
min for 90 min. Survey scans were acquired from m/z
400–1800 with up to four precursors selected for MS/
MS from m/z 100–2000. Each SCX fraction was ana-
lyzed in duplicate.
Data analysis
The MS/MS spectra were extracted and searched against
the Swissprot database (HUMAN 090210) using Protein-
Pilot software (version 3.0, revision 114732, Applied Bio-
systems). The following parameters were set in the
searching: trypsin as enzyme, iTRAQ as sample type, no
special factors, biological modification, thorough identi-
fication search, etc. Using the following criteria to con-
sider a protein for further statistical analysis: unused
ProtScore >1.3 with at least one peptide with 95% confi-
dence per repetition. The candidate proteins were exam-
ined in the Protein ID of the Protein Pilot software.
Protein expression ratios were computed on basis of the
peak area ratios of the peptides accounting for the same
protein. All of the normalized peptides of a protein were
then averaged and the standard deviation of the meanTable 1 Clinical information of patients
Variable Kidney t
Recipient gender, n (% female)
Recipient age, mean± SD 38
Creatinine at Tx [μmol/L], mean± SD 2105
Creatinine at one month after Tx [μmol/L], mean± SD 127
Hemoglobin at Tx [g/L] 10
Systolic blood pressure [mmHg], mean± SD 12
Diastolic blood pressure [mmHg], mean± SD 78
PRA> 20 % (%)
HLA-mismatches, median (range)
Immunosuppressive treatment FK506/Pred/MMF, n (%)
CsA/Pred/MMF, n (%)
7
Post-Tx immunologic rejection in half year,n (%)
Tx, Transplantation; HLA, Human leukocyte antigen; PRA, Panel reactive antibody; Fwas determined for each protein. The bias correction al-
gorithm was applied to correct for unequal mixing dur-
ing the combination of the different labeled samples,
based on the assumption that most proteins do not
change in expression. All quant ratios (both the average
ratio for proteins and the individual peptide ratios) were
corrected for the bias.Analysis of regulatory networks
MetaCore (GeneGo, St. Joseph, MI) is used for functional
analysis of experimental data from high-throughput ex-
pression assays. The software has a curated database of
human protein–protein and protein–DNA interactions,
transcriptional factors, signaling, metabolism, and bio-
active molecules. The software analyzes the input gene
sets and develops a list of relevant biological networks
that not only link the gene members in the clusters, but
also provide the functionality to identify the co-regulated
genes ranked by statistics and scores. All networks ana-
lyzed in this study were constructed by use of the default
settings and values under analysis network option. To
functionally annotate the differentially expressed proteins
identified in this study, the proteins (≥2.0-fold change)
were entered into GeneGo’s MetaCore for analysis. The
genes encoding expressed overabundant proteins were
used as the input list for generation of regulatory net-
works using Transcription Regulation algorithm which
generated sub-networks centered on transcription fac-
tors. Sub-networks are ranked by a P-value and inter-
preted in terms of Gene Ontology. For every transcription
factor (TF) with direct target(s) in the root list, this algo-
rithm generated a sub-network consisting of all shortest
paths to this TF from the closest receptor with direct
ligand(s) in the root list.ransplantation
(n =8)
Combined hematopoietic stem cells and
kidney transplantation (n =4)
37.50 % 0
.00 ± 12.70 33.00 ± 2.16
.75 ± 318.69 1569.25 ± 458.77
.00 ± 47.65 110.50 ± 10.89
2 ± 32.32 104.00 ± 16.51
2.25 ± 8.97 140.00 ± 28.28
.75 ± 6.41 90.00 ± 20.00
0 25 %
1.5(0–4) 0.5(0–3)
5 % 25 % 75 % 25 %
37.5 % 0
K506, Tacrolimus; Pred, Prednisone; MMF, Mycophenolate; CsA, Cyclosporine.
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Five proteins were analyzed by ELISA based on commer-
cially available kits following themanufacturers’ directions:
Human ApoA1, ApoB, Fibrinogen (Abcam,UK), C3a,
C5a (Hycult biotech, The Netherlands). All samples were
analyzed in triplicates. The independent samples t-test
was used to compare mean difference between patients
of Tx and C+Tx groups. Mann–Whitney U tests were
utilized to compare the medians of plasma concentration
of C3a and C5a in patients with and without HSC.
P value <0.05 is considered as significant. All of the
statistical analysis was implemented using SPSS15.0
software.
Results
The allograft function, the clinical course, and the allo-
graft biopsy results of two groups were extracted as
Table 1. In Tx group, patients received 7–34 months fol-
low up. For most recipients, serum creatinine (SCr) was
stable, ranging from 105 to 152umol/l at their most re-
cent out-patient appointment. Three of the eight patientsFigure 1 Biologic processing of expressed proteins. Comparison of the
Tx and C+ Tx (Figure 1B) are shown. Each enumerated annotation is assign
enumerated annotations and fractions of identified proteins that belong towithout cell therapy experienced acute rejection. Al-
though only four patients with HSC transplantation were
analyzed by proteomics study in the present paper, a total
of nine cases were performed in our stem cell research
(Additional file 1: Table S1). The patients with cell trans-
plantation had no immunologic rejection during the
six months following surgery. These patients received
1–29 months follow up. Although immunosuppressant
dosages were gradually reduced, most patients main-
tained stable kidney function. There were no incidents
of severe infection requiring hospitalization among
these patients. Microchimerism was detected to evaluate
the HSC transplant efficiency. For example, in patient 1,
the microchimerism appeared in bone marrow 21 days
after transplantation and peripheral blood 28 days after
transplantation with a chimeric ranging from 30% to
50%. The microchimerism could also be detected in
peripheral blood 42 days after transplantation, but van-
ished 6 months after transplantation. However, the rate
of microchimerism in other patients without HSC trans-
plant ranged from 1% to 5%.expressed proteins between pre-Tx and C+ Tx groups (Figure 1A),
ed by the enrichment score represented as P value. The table lists the
that particular biologic process category.
Figure 2 Comparison of the plasma concentrations of
complement C3a and C5a. Plasma concentrations of complement
C3a (Figure 2A), and C5a (Figure 2B) in patients of C + Tx and Tx
groups. The plasma C3a and C5a concentration in Tx patients were
significantly higher than those in C+ Tx patients (P= 0.027 and 0.017,
respectively).
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tides corresponding to 179 unique proteins and shared
an overlap of 78% of the total unique proteins of the
combined data. The overlapping proteins were submit-
ted for further analysis . Proteins from Pre-Tx, C +Tx,
and Tx patients were labeled with 113, 115, and 119
tags, respectively. The ratios 113:115 and 119:115 indi-
cate the relative abundance of proteins in Pre-Tx, Tx
with respect to C +Tx. The upper and lower ranges
worked out to be 2.0 and 0.5, respectively. In other
words, proteins with iTRAQ ratios below the lower
range were considered to be under-expressed, while
those above the higher range were considered overex-
pressed. A total of 73 proteins showed an abundance
change of at least two fold in Pre-Tx compared to C+Tx
group: 39 were over-expressed and 34 were under-
expressed in Pre-Tx. Meanwhile, with respect to Tx
patients, 65 proteins including 36 over-expressed and 29
under-expressed proteins were detected in C+Tx.
We used Metacore pathway mapping tool to analyze
and build the gene ontology processes involved in the dif-
ferentially expressed proteins. The differentially expressed
protein between Pre-Tx and C+Tx were mapped into: 1
response to wounding; 2 response to external stimulus;
3 acute inflammatory response. Except the processes
above, GO analysis showed plasma lipoprotein particle
remodeling, protein-lipid complex remodeling, macro-
molecular complex remodeling play a role in cell ther-
apy. Selected results are shown in Figure 1.
The concentrations of complement C3a, and C5a in
plasma from patients in Tx and C+Tx group are shown in
Figure 2. The plasma concentrations of C3a (Figure 2A)
and C5a (Figure 2B) were significantly higher in Tx
patients than in C +Tx patients (C3a: Tx, median,
134.88 ng/ml; range, 31.62–157.0 ng/ml; C +Tx, me-
dian, 33.67 ng/ml; range, 13.68–83.10 ng/ml; C5a: Tx,
median, 56.45 ng/ml; range, 28.82–181.46 ng/ml;
C +Tx, median, 17.41 ng/ml; range, 8.36–31.07 ng/ml;
P = 0.027 and 0.017, respectively).
Plasma expression level of coagulation and comple-
ment proteins was significant changed when comparing
protein profile between Tx and C+Tx (Figure 3). Fi-
brinogen level was significantly lower in C+Tx group.
The result in proteomics analysis was consistent with the
findings of ELISA test in patients (Table 2). Meanwhile, a
subset of lipoproteins such as protein Apolipoprotein-A1
(ApoA1), ApoC1, ApoA2, ApoE, ApoB were found to be
significantly lower in Tx group compared to C+Tx
group. For example, ApoA1 was 0.2 fold lower in Tx
group. The expression level of ApoA1 and ApoB has
been verified by using ELISA method (Table 2).
Based on differentially expressed data in patients with
or without hematopoietic-cell transplantation, represen-
tative transcription regulatory networks have beendeveloped by using MetaCoreTM network software and
the Analyze Network algorithm. Any object containing
the most connections to the root objects may represent
key regulators in the clustered genes. Nuclear factor-κB
(NF-κB), signal transducer and activator of transcription
3 (STAT3), signal transducer and activator of transcrip-
tion 1 (STAT1) as the top three key objects found in the
transcription regulatory networks. STAT1 is an acute-
phase response factor and it has positive effect on
complement and coagulation activation. GO processes
Figure 3 NF-κB and STAT1 network. Representative transcription regulatory networks based on differentially expressed data in patients with or
without hematopoietic-cell transplantation using MetaCore™ network software and the Analyze Network algorithm. Two representative networks
are shown: (3A) the NF-κB network and (3B) the STAT1 network. NF-κB and STAT1 are acute-phase responsive factors which are involved in
the regulation of complement activation and,coagulation as well as their intercommunication. Red circles in the right corner of a gene indicate
up-regulation and blue circles down-regulation.
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adjusting to stress (100.0%) and positive regulation of
cholesterol esterification (33.3%).Discussion
At present, HSC transplantation is a potential method
for the induction of immunologic tolerance. Although
persistence of mixed chimerism may contribute to toler-
ance induction in combined kidney and HSC transplant-
ation, very few clinical trials and mechanism studies are
available to support this hypothesis. Through proteomic
and bioinfomatic analysis of differentially expressed pro-
teins, our study provides novel insight into the molecu-
lar events of HSC-induced immunologic tolerance.
The pre-Tx group was comprised of patients with
renal failure. An imbalance of destructive and reparative
cellular processes contributes to the clinicopathologic
entity of renal failure. Kidney transplantation is consid-
ered the treatment of choice for many people with se-








144. 13 ± 61.00 240.01 ± 62.44*
Apolipoprotein
B(mg/dl)
78. 82 ± 23.44 133.36 ± 31.87*
Fibrinogen(mg/dl) 374.25 ± 28.12 278.50 ± 26.10*
*P< 0.05 vs Kidney transplantation group.survival are often better than in people who use dialysis.
It is evident from Figure 1A that transplantation could
be considered as the biologic procedure of decreasing
stress-related, immune/inflammatory, and tissue injury.
The present study reveals that lipoprotein metabolism
plays a role in HSC-induced immunologic tolerance. In
our study, the plasma levels of lipoproteins such as
ApoA1 in C+Tx group were much higher than the
patients without cell therapy compared to patients re-
ceiving HSC transplantation. A previous study demon-
strated that lipoprotein abnormalities were associated
with mild impairment of kidney function [11]. The pro-
tein Apo A1 was significantly lower at rejection com-
pared with post-rejection [11]. Apo A1 may produce a
plasma molecular profile which is associated with acute
cellular renal allograft rejection [12]. Additionally,
changes in amino acid and lipoprotein metabolism could
potentially lead to alterations of the vascular wall, anor-
exia, endocrine dysfunction, and altered muscle intracel-
lular signaling in chronic kidney disease. Therefore,
normal lipoprotein metabolism was related with stable
kidney function and decreased risk for vascular disease
in chronic kidney disfunction [13].
In Figure 3A and Table 2, in comparison with Tx
group, the C+Tx group exhibited a lower plasma level
of fibrinogen. Given that kidney regeneration is a major
predictor of outcome for patients with kidney damage,
the role of fibrinogen in diagnosis, prevention, and
therapeutic intervention of kidney disease has been
emphasized [14]. Our previous study demonstrated that
a hypercoagulable state existed in acute renal rejection
patients, as evidenced by high levels of circulating
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plasma glycoprotein may be elevated in any form of in-
flammation, but hyperfibrinogenemia in patients with
kidney transplantation can deteriorate renal function
and predict high-risk cardiovascular diseases [15]. The
mechanism of rejection in solid organ transplantation is
influenced by the initial inflammatory response and sub-
sequent adaptive allo-immune response, both of which
have been shown to be affected by various complement
components [16]. There is growing evidence that exces-
sive complement can be harmful to the host [17]. In
Figure 3A, most complement-related proteins including
C3, C3a, C3b, C3c, C3dg,C4BP were upregulated in Tx
group when compared with C +Tx group; Our findings
suggests HSC therapy regulates the activation of comple-
ment via both the classical (serpin peptidase inhibitor
and C4BP) and the alternative pathways (complement
factors B, D, H, I, and C3) but not the lectin pathway.
A crosstalk event occurs between complement and the
coagulation system, apparently with the objective of en-
hancing local clotting and preventing microbial spread
in the circulation system [18,19]. As we know, C3a and
C5a play the key role in the tight regulation of activation
process of the complement system [16]. Previous find-
ings suggested [20] that an early hyper-activation of
complement with generation of powerful anaphylatox-
ins, such as C3a and C5a, which may contribute to the
disturbance of the coagulation system. Complement
amplifies coagulation and inhibits fibrinolysis, mainly
through C5a, which induces the expression of tissue fac-
tor [21] and plasminogen-activator inhibitor 1. In the
present study, transcription regulation analysis by devel-
oping network showed NF-kB (Figure 3A), STAT1
(Figure 3B) are acute-phase responsive factors which
play pivotal roles in the regulation of the complement
activation and coagulation as well as their intercom-
munication. Which suggests in accordance with other
reports [22,23] that NF-kB and STAT1 are associated
with complement and coagulation cascades. Therefore, it
is tempting to speculate that these significant interac-
tions between the coagulation and complement system
may play an important role after transplantation and for
subsequent inflammatory and immunologic reactions.
However, more validation and evidence is needed for
further understanding.
This study presents a direct proteomic evidence that
attenuating complement and coagulation activations is a
key process in HSC-induced immunologic tolerance.
The present study also indicates that stem cell trans-
plantation contributes to the regulation of lipoprotein
metabolism which is associated with kidney function.
Therefore, this study provides insight into the molecular
events in the HSC-induced immunologic tolerance and
will help our design of new strategies for treatment.Additional file
Additional file 1: Table S1. Clinical information of patients with cell
transplantation. Table S2. Doses of immunosuppressive agents in
patients with combined cell and kidney transplantation. Table 3.
Transcription Factor Targets Modeling Workflow Report.
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